Global Viral Infections Market to Reach US$117.6 bn by 2021, Increasing Patients Pool Suffering from Viral Infections to Drive Growth

Published Date : May 23, 2016

ALBANY, New York, May 23, 2016 has announced the addition of a new study on the global market for viral infections to its vast repository. The research report, titled “Global Viral Infections Market To 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics,” offers a comprehensive overview of this market, underlining the major trends and opportunities that it is likely to witness between 2015 and 2021.

This 179-page market study, with the help of 4 tables and 75 figures, presents a detailed overview of the worldwide viral infection market, taking various factors such as driving forces, challenges, the growth rate, and the future prospects of this market in consideration.

According to the research study, the global market for viral infections stood at US$74 bn in 2014. Analysts project this market to rise at a CAGR of 6.80% from 2015 to 2021 and reach an estimated value of US$117.6 bn by the end of the forecast period.

The increasing pool of patients suffering from chronic viral infections such as influenza, HIV, hepatitis B, and hepatitis C and the availability of advanced treatment options are expected to fuel the demand for viral infections therapeutics significantly over the forecast period. Another important factor projected to propel the global market for viral infections in the coming years is the implementation of rules and policies improving access to treatment for people in remote localities.

For Sample Copy, click here:

Apart from these, the increasing costs of these treatments owing to the adoption of newly approved, expensive antiviral agents and late-stage potential candidates that are projected to be highly-priced, are likely to boost this market remarkably in the near future, notes the research study.

The report further states that around 1,848 pipeline products are being particularly developed for the treatment of viral infections, acquiring a considerable proportion of the product pipeline of infectious disease therapeutics.

Among these therapies, HIV has the highest number of products, i.e. 419 products at an active development stage, which is followed by influenza with 333 products, Hepatitis C with 222 products, and Hepatitis B with 150 pipeline products at the active development stage. Atripla, Truvada, and Harvoni are some of the currently marketed products that have garnered immense commercial success, states the market study.

The US, the UK, Germany, Spain, France, Italy, and Japan have been identified as the key regional markets for viral infections therapeutics in this research report. The study also assesses the competitive landscape of the worldwide viral infections market by evaluating the profiles of the major market players. Abbott Laboratories Inc., Becton, Dickinson and Co., and Thermo Fisher Scientific Inc. are some of the major companies operating in this market.

The main objective of this research report is to provide a clear picture of the global viral infections market to companies and stakeholders operating in this market and assist them in the expansion of their businesses.

To order report Call Toll Free: 866-997-4948 or send an email on